Title: Advancing Home-Based Diagnostics and Care: Nanowear and Satio Partner for Precision Healthcare
In a groundbreaking collaboration, Nanowear and Satio have joined forces to revolutionize patient-friendly, home-based diagnostic and therapeutic care. This partnership combines Nanowear’s AI-based nanotechnology biomarker diagnostic platform with Satio’s blood draw diagnostics and drug delivery systems. By integrating in vivo and in vitro diagnostics, this collaboration aims to provide precision therapeutics and individualized AI-based risk assessment for patients.
The adoption of home-based digital care has been steadily increasing since 2019, with patients, healthcare systems, pharmaceutical companies, and medtech firms embracing this convenient and cost-effective approach. However, challenges such as accuracy, reliability, cost, workflow integration, and limited access to actionable data have hindered widespread adoption. This partnership between Nanowear and Satio seeks to address these barriers and provide more seamless and effective solutions in remote healthcare.
Nanowear is at the forefront of transforming home-based cardiometabolic healthcare with its FDA-approved cloth nanotechnology and AI diagnostics platform, SimpleSense™. This platform offers a comprehensive cardiometabolic assessment and continuous monitoring of health indicators, all from the comfort of the patient’s home. By collecting 85+ clinically validated biomarkers simultaneously, SimpleSense™ replaces traditional diagnostic tools and provides a more holistic view of the patient’s health.
Satio, on the other hand, is focused on decentralizing care through its patch-based adhesive technology for blood-based diagnostics and drug delivery procedures. With a recent accolade from the Advanced Research Development Agency for Health ARPA-H Challenge program, Satio is leading the way in remote healthcare delivery. This partnership with Nanowear further accelerates Satio’s efforts to shift care from clinics to the home and enhance information capture and analytics for better patient outcomes.
Together, Nanowear and Satio are exploring various collaboration pathways to advance home-based diagnostics and care. One key initiative involves integrating Satio’s blood draw patches with Nanowear’s SimpleSense system, creating a unique combination of blood and genotype biomarkers with cardiometabolic data. This innovative approach is set to revolutionize clinical research and home-based care, with a market value of approximately $55 billion annually.
“We are excited about merging in vitro and in vivo results to enhance chronic disease management and drug delivery,” says Namal Nawana, Chairman and Founder of Satio. “This partnership will strengthen information flow and decision-making for both patients and clinicians, ultimately improving outcomes.”
Venk Varadan, CEO, and Co-founder of Nanowear, emphasizes the importance of combining key health determinants to unlock early diagnosis and precision medicine. By integrating technologies that capture various biomarkers, this partnership aims to provide a comprehensive platform for personalized healthcare.
The collaboration between Nanowear and Satio aligns with the evolving landscape of digital health post-2020 pandemic. By synchronously combining relevant biomarkers and leveraging AI for precision medicine, this partnership has the potential to improve patient health and alleviate the strain on healthcare systems.
In conclusion, the partnership between Nanowear and Satio represents a significant step forward in home-based diagnostics and care. By integrating cutting-edge technologies and leveraging AI for precision medicine, this collaboration aims to enhance patient outcomes and revolutionize the healthcare industry. Stay tuned for more updates on this innovative partnership and the impact it will have on the future of healthcare.
